Rethinking UK Market Access: CE Mark Recognition May Be Here to Stay

The United Kingdom is once again signaling a meaningful shift in its post-Brexit regulatory strategy for medical devices. Recent discussions from the MHRA suggest a potential long-term, and possibly indefinite, recognition of CE-marked devices in Great Britain, marking a pragmatic evolution in how the UK approaches market access for MedTech.

Rather than fully separating from EU regulatory frameworks, the UK appears to be reassessing the balance between autonomy and practical alignment, particularly in light of ongoing implementation challenges and supply chain considerations.

A regulatory direction shaped by market reality

Since Brexit, the UK has aimed to establish the UKCA marking system as its independent conformity assessment pathway. However, the transition has been slower and more complex than initially anticipated.

Several structural realities are now influencing the conversation:

• A significant majority of devices in the UK market (around 90%) continue to rely on CE marking
• The UKCA transition has faced capacity constraints across the conformity assessment ecosystem
• Concerns remain that a strict discontinuation of CE recognition could create unnecessary regulatory friction and potential supply disruptions

Against this backdrop, regulatory continuity is increasingly being viewed not just as an administrative choice, but as a mechanism to safeguard access to medical technologies.

What is currently being considered

The MHRA is exploring a more flexible and phased regulatory approach that would reshape how CE-marked devices are treated in Great Britain. Key proposals under discussion include:

• Extending the acceptance of legacy MDD-certified devices until 2028
• Maintaining recognition of devices certified under the EU MDR/IVDR frameworks
• Introducing a more streamlined regulatory pathway for higher-risk devices requiring additional oversight

While not a formal policy change yet, these directions indicate a clear recalibration of the original UKCA implementation strategy.

From divergence to pragmatic alignment

If adopted, these measures would represent an important strategic pivot in the UK’s regulatory posture.

Rather than fully decoupling from the EU system, the UK would be moving toward a model that prioritizes:

• Regulatory efficiency over duplication
• Market continuity over structural separation
• Predictability for manufacturers operating across multiple jurisdictions

This does not eliminate UK regulatory sovereignty, but it does suggest a more balanced approach—where alignment with existing global frameworks becomes a tool for stability rather than dependency.

Implications for MedTech manufacturers

For global manufacturers and regulatory teams, this potential shift carries several important implications:

Reduced regulatory duplication
Leveraging CE certification for UK access could significantly reduce parallel submission burdens.

Improved speed to market
Streamlined recognition pathways may allow faster commercialization in Great Britain.

Greater strategic alignment across regions
Companies may benefit from more harmonized EU–UK regulatory strategies, optimizing resources and submission planning.

Increased predictability in a shifting landscape
A longer-term recognition model would provide clarity in a regulatory environment that has remained in transition since Brexit.

A key moment for global regulatory strategy

The UK’s evolving stance reflects a broader global trend in MedTech regulation: a gradual shift toward convergence and pragmatism in response to increasing complexity, innovation cycles, and global supply interdependence.

For companies operating internationally, these developments reinforce the importance of adaptable regulatory strategies that can respond to evolving alignment between major markets.

Final perspective

The potential long-term recognition of CE-marked devices in Great Britain represents more than a technical adjustment. It reflects a broader rethinking of how regulatory systems can balance independence with practicality in a highly interconnected global MedTech ecosystem.

As the situation continues to evolve, staying ahead of these shifts will be critical for manufacturers seeking to maintain efficient and compliant global market access strategies.

At Arazy Group, we continue to monitor these developments closely, supporting MedTech companies in navigating regulatory change and optimizing their global market access strategies with clarity and confidence.